JP2015503658A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503658A5
JP2015503658A5 JP2014550287A JP2014550287A JP2015503658A5 JP 2015503658 A5 JP2015503658 A5 JP 2015503658A5 JP 2014550287 A JP2014550287 A JP 2014550287A JP 2014550287 A JP2014550287 A JP 2014550287A JP 2015503658 A5 JP2015503658 A5 JP 2015503658A5
Authority
JP
Japan
Prior art keywords
compound according
compound
kda
galactose
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014550287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503658A (ja
JP6133894B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/055311 external-priority patent/WO2013101314A1/en
Publication of JP2015503658A publication Critical patent/JP2015503658A/ja
Publication of JP2015503658A5 publication Critical patent/JP2015503658A5/ja
Application granted granted Critical
Publication of JP6133894B2 publication Critical patent/JP6133894B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014550287A 2011-12-28 2012-09-14 ヒト疾患処置用の新規糖薬剤の組成物 Active JP6133894B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580830P 2011-12-28 2011-12-28
US61/580,830 2011-12-28
PCT/US2012/055311 WO2013101314A1 (en) 2011-12-28 2012-09-14 Composition of novel carbohydrate drug for treatment of human diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017083834A Division JP6262386B2 (ja) 2011-12-28 2017-04-20 ヒト疾患処置用の新規糖薬剤の組成物

Publications (3)

Publication Number Publication Date
JP2015503658A JP2015503658A (ja) 2015-02-02
JP2015503658A5 true JP2015503658A5 (cg-RX-API-DMAC7.html) 2015-11-05
JP6133894B2 JP6133894B2 (ja) 2017-05-24

Family

ID=48698494

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014550287A Active JP6133894B2 (ja) 2011-12-28 2012-09-14 ヒト疾患処置用の新規糖薬剤の組成物
JP2017083834A Active JP6262386B2 (ja) 2011-12-28 2017-04-20 ヒト疾患処置用の新規糖薬剤の組成物
JP2017238700A Active JP6415677B2 (ja) 2011-12-28 2017-12-13 ヒト疾患処置用の新規糖薬剤の組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017083834A Active JP6262386B2 (ja) 2011-12-28 2017-04-20 ヒト疾患処置用の新規糖薬剤の組成物
JP2017238700A Active JP6415677B2 (ja) 2011-12-28 2017-12-13 ヒト疾患処置用の新規糖薬剤の組成物

Country Status (14)

Country Link
US (9) US8871925B2 (cg-RX-API-DMAC7.html)
EP (1) EP2797942B1 (cg-RX-API-DMAC7.html)
JP (3) JP6133894B2 (cg-RX-API-DMAC7.html)
KR (1) KR101968370B1 (cg-RX-API-DMAC7.html)
CN (1) CN104245717B (cg-RX-API-DMAC7.html)
AU (2) AU2012363033B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014015940B1 (cg-RX-API-DMAC7.html)
CA (1) CA2861492C (cg-RX-API-DMAC7.html)
DK (1) DK2797942T3 (cg-RX-API-DMAC7.html)
ES (1) ES2699386T3 (cg-RX-API-DMAC7.html)
IL (1) IL233313A (cg-RX-API-DMAC7.html)
MX (1) MX363923B (cg-RX-API-DMAC7.html)
WO (1) WO2013101314A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505849B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
CN104245717B (zh) 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
WO2013184892A1 (en) * 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
JP6415437B2 (ja) 2012-09-17 2018-10-31 ガレクティン・セラピューティクス・インコーポレイテッドGalectin Therapeutics, Inc. 癌の処置における特異的免疫療法を向上する方法
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
GB201502668D0 (en) * 2015-02-17 2015-04-01 Glycomar Ltd And Albert Bartlett & Sons Airdrie Ltd Method for isolation of polysaccharides
FR3036943A1 (fr) * 2015-06-02 2016-12-09 Echosens Dispositif non invasif de detection de lesion hepatique
US20190367552A1 (en) * 2016-03-04 2019-12-05 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
EP3568139A4 (en) * 2017-01-13 2020-10-28 Sivanaray, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR THE PREVENTION OR TREATMENT OF LIVER AND LIPID RELATED DISEASES
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
DE102019003442A1 (de) 2019-05-15 2020-11-19 Ilma biochem GmbH Verwendung von niedermolekularen glykosidisch gebundenen endständigen Galactosiden und Fucosiden zur Bindung von als Galectin wirkenden Toxinen im Rahmen der Behandlung von Vergiftungen, insbesondere bei Vergiftungen mit Ricin
WO2021064729A1 (en) * 2019-10-02 2021-04-08 Patchor Ltd. Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
EP4181910A4 (en) * 2020-07-17 2024-06-05 DSM Nutritional Products, LLC OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE
CN116211884B (zh) * 2023-02-16 2024-05-17 海孵(海南自贸区)医疗科技有限责任公司 一种鼻腔喷雾剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2132577A (en) 1934-08-28 1938-10-11 Gen Foods Corp Method of preparing pectin
US2444266A (en) 1944-03-31 1948-06-29 Us Agriculture Pectic materials and method of preparing same
US2503258A (en) 1948-01-23 1950-04-11 Us Agriculture Neutralization of pectinic acids with sodium bicarbonate
US4016351A (en) 1976-02-04 1977-04-05 Eschinasi Emile H Pectic substances with varying methoxyl content and process therefor
US4268533A (en) 1979-11-21 1981-05-19 General Foods Corporation Quick-set low methoxyl pectin composition
JPS61502124A (ja) * 1984-05-09 1986-09-25 ジ オ−ストラリアン ナシヨナル ユニヴア−シテイ− 免疫応答の調節方法
US4686106A (en) 1986-06-16 1987-08-11 General Foods Corporation Pectin food product
US5071970A (en) 1988-11-23 1991-12-10 University Of Florida Process for producing pectin with a high-to-medium methoxyl content from beet pulp
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7491708B1 (en) 1993-03-01 2009-02-17 David Platt Modified pectin
JP3360899B2 (ja) 1993-10-08 2003-01-07 日本医薬品工業株式会社 癌予防・治療剤
US5498702A (en) 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6632797B2 (en) 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
KR100252194B1 (ko) 1997-10-10 2000-04-15 박호군 참당귀에서분리한신규한펙틴질다당류와그분리정제방법및그의면역증강제로서의용도
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US20040121981A1 (en) 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
KR100594353B1 (ko) 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
JP2004107295A (ja) * 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
US20040223971A1 (en) 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
EP1980257A1 (en) * 2003-04-07 2008-10-15 Prospect Therapeutics, Inc. Compositions and uses of galectin antagonists
WO2004096998A2 (en) 2003-04-29 2004-11-11 Vanderbilt University Nanoparticular tumor targeting and therapy
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1765874A1 (en) 2004-03-26 2007-03-28 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
KR101074158B1 (ko) * 2008-04-07 2011-10-17 재단법인 한국원자력의학원 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물
US9646327B2 (en) 2011-08-09 2017-05-09 Yahoo! Inc. Disaggregation to isolate users for ad targeting
CA2848711C (en) 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104245717B (zh) 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
WO2013184892A1 (en) * 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
JP6415437B2 (ja) 2012-09-17 2018-10-31 ガレクティン・セラピューティクス・インコーポレイテッドGalectin Therapeutics, Inc. 癌の処置における特異的免疫療法を向上する方法
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis

Similar Documents

Publication Publication Date Title
WO2009033799A3 (en) Use of a peptide as a therapeutic agent
WO2009033667A3 (en) Use of a peptide as a therapeutic agent
WO2009039990A3 (en) Use of icam peptide as a therapeutic agent
WO2009033805A3 (en) Use of somatostatin-14 as a therapeutic agent
WO2009033758A3 (en) Use of the peptide phpfhffvyk as therapeutic agent
WO2009040036A3 (en) Use of a galanin peptide as a therapeutic agent
WO2009033789A3 (en) Use of a peptide as a therapeutic agent
WO2009033747A3 (en) Use of a peptide as a therapeutic agent
WO2009049742A3 (en) Use of melanotrophin-potentiating factor as a therapeutic agent
WO2009046867A3 (en) Caerulein alone or in combination with acth (3-24 ) as therapeutic agent
WO2009033737A3 (en) Use of gluten exorphin c : as a therapeutic agent
WO2009033741A3 (en) Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
WO2009040073A3 (en) Use of a peptide as a therapeutic agent
WO2009039986A3 (en) Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent
WO2009033714A3 (en) Use of a peptide as a therapeutic agent
WO2009043440A3 (en) Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
WO2009046860A3 (en) Use of dago as a therapeutic agent
WO2009033729A3 (en) Therapeutic uses of gastrin- 1 and g- pen-grgdspca
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
NZ742220B2 (en) Pharmaceutical compositions comprising meloxicam